Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to $43.6 million.

  • BIO-TECHNE's Accumulated Expenses rose 3.86% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 3.86%. This contributed to the annual value of $65.8 million for FY2025, which is 32.06% up from last year.
  • Latest data reveals that BIO-TECHNE reported Accumulated Expenses of $43.6 million as of Q3 2025, which was down 33.73% from $65.8 million recorded in Q2 2025.
  • Over the past 5 years, BIO-TECHNE's Accumulated Expenses peaked at $65.8 million during Q2 2025, and registered a low of $28.6 million during Q4 2022.
  • Moreover, its 3-year median value for Accumulated Expenses was $43.6 million (2025), whereas its average is $45.8 million.
  • In the last 5 years, BIO-TECHNE's Accumulated Expenses spiked by 84.70% in 2021 and then slumped by 40.69% in 2023.
  • Over the past 5 years, BIO-TECHNE's Accumulated Expenses (Quarterly) stood at $43.9 million in 2021, then tumbled by 34.81% to $28.6 million in 2022, then climbed by 15.23% to $33.0 million in 2023, then skyrocketed by 62.43% to $53.6 million in 2024, then increased by 3.86% to $43.6 million in 2025.
  • Its last three reported values are $43.6 million in Q3 2025, $65.8 million for Q2 2025, and $61.9 million during Q1 2025.